AbbVie Inc (ABBV)vsEntrada Therapeutics Inc (TRDA)
ABBV
AbbVie Inc
$294.48
-0.18%
HEALTHCARE · Cap: $521.11B
TRDA
Entrada Therapeutics Inc
$5.17
-4.96%
HEALTHCARE · Cap: $177.16M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1408649% more annual revenue ($66.01B vs $4.69M). ABBV leads profitability with a 15.7% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
TRDA
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$294.48
$137.19 premium
Intrinsic value data unavailable for TRDA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : TRDA
The strongest argument for TRDA centers on Price/Book, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : TRDA
The primary concerns for TRDA are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a mature stock while TRDA is a value play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.23 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 29/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Entrada Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Entrada Therapeutics Inc. (TRDA) is a forward-thinking biotechnology company focused on creating innovative therapies for severe diseases characterized by significant unmet medical needs. Leveraging its proprietary Therapeutics for RNA Delivery (TRADA) platform, Entrada aims to tackle RNA and protein dysfunctions associated with muscular dystrophies and genetic disorders. The company has developed a robust clinical pipeline underscored by a commitment to scientific excellence and is led by a seasoned management team with extensive industry expertise. With its strategic focus and cutting-edge therapeutic solutions, Entrada is well-positioned to drive meaningful advancements in patient care and establish itself as a leader in the biopharmaceutical sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?